Multiply Labs Expands Collaboration with Thermo Fisher Scientific to Automate Cell Therapy Manufacturing

SAN FRANCISCO, CA – September 30, 2025– Multiply Labs, a San Francisco-based robotics company developing advanced automated manufacturing systems for cell therapies, today announced an expansion of its collaboration with Thermo Fisher Scientific, the world leader in serving science. The enhanced collaboration will focus on integrating Thermo Fisher’s automated Gibco™ CTS™ DynaCellect™ Magnetic Separation System with Multiply Labs’ state-of-the-art robotic platforms. 

The Gibco™ CTS™ DynaCellect™ System is a closed, automated isolation, activation and bead removal system for cell therapy development and manufacturing. Together with fit-for-purpose consumables, it offers high cell purity, recovery and viability. By combining the Gibco™ CTS™ DynaCellect™ System with Multiply Labs’ robotic automation expertise, the collaboration will accelerate critical steps in cell therapy production by reducing manual intervention and improving process consistency.

“Thermo Fisher is committed to advancing cell therapy manufacturing through innovative, scalable solutions,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “Our expanded collaboration with Multiply Labs will enable customers to achieve end-to-end automation in their manufacturing processes, ultimately accelerating the delivery of transformative therapies to patients.”

Multiply Labs’ robotic systems are designed to automate complex biomanufacturing workflows, enabling high-throughput, flexible production of cell therapies. Integrating these capabilities with the Gibco™ CTS™ DynaCellect™ System will enhance customers’ ability to achieve seamless, end-to-end cell separation and processing.

“We are excited about continuing to integrate leading, GMP-ready instruments with our robotic technology,” said Fred Parietti, PhD, Co-Founder and CEO of Multiply Labs. “This extended partnership is another step toward fully autonomous cell therapy manufacturing, reducing costs, minimizing human error, and ultimately getting treatments to patients faster.”

This collaboration builds on the companies’ existing collaboration, which has focused on automating cell expansion and separation processes, including the Heracell™ VIOS Automated Access CO2 Incubator and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System.